The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Promising early-phase trials exploiting MTAP deletion in mesothelioma
Paolo Bironzo, MD, PhD, University of Turin, Turin, Italy, comments on promising early-phase trial updates in mesothelioma. Exploiting MTAP deletions through PRMT5 and MTAP inhibitors have been touted as another future treatment avenue, with multiple trials currently exploring these agents in mesothelioma. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the most promising updates were from early-phase trials in mesothelioma. Some of them were presented last year at ESMO and suggested that, for example, the Hippo pathway can be targeted with novel agents, such as TEAD inhibitors. There are plenty of Phase 1 trials that suggest interesting response rates and durability of responses, and now at least one of these agents is moving to a Phase 3 trial in pretreated patients...
I think that the most promising updates were from early-phase trials in mesothelioma. Some of them were presented last year at ESMO and suggested that, for example, the Hippo pathway can be targeted with novel agents, such as TEAD inhibitors. There are plenty of Phase 1 trials that suggest interesting response rates and durability of responses, and now at least one of these agents is moving to a Phase 3 trial in pretreated patients. And then the other important approach that may allow us to treat some patients with mesothelioma in the future is exploiting MTAP deletions. So, PRMT5 and MAT2A inhibitors in this disease. There are plenty of trials and trial designs that are trying to explore these kinds of agents, even in this tumor type. Regarding the Hippo pathway, I would say that this Phase 3 trial is eagerly awaited and is expected to start in the next few months, at least in the US, and then globally.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
